MEI Pharma Updates On Ongoing Phase 1 Study Evaluating Oral CDK9 Inhibitor Voruciclib Alone and in Combination with Venetoclax in Patients with Acute Myeloid Leukemia or B-Cell Malignancies
Portfolio Pulse from Benzinga Newsdesk
MEI Pharma announced an update to the Phase 1 study evaluating voruciclib, an oral CDK9 inhibitor, in patients with acute myeloid leukemia or B-cell malignancies. The results show that voruciclib alone or in combination with venetoclax was well tolerated with no significant myelosuppression and demonstrated encouraging clinical activity.
May 23, 2023 | 12:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
MEI Pharma's Phase 1 study update on voruciclib shows promising results and a well-tolerated combination with venetoclax for AML and B-cell malignancies.
The positive results from the Phase 1 study of voruciclib indicate that the drug is well-tolerated and demonstrates encouraging clinical activity. This could potentially lead to increased interest in MEI Pharma's stock and a positive short-term impact on its price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100